Novartis’ Entresto Gains US FDA Panel Nod For New Heart Failure Claim
Executive Summary
But advisory committee members debate how to define the target population for a new indication, shying away from use of ‘preserved’ to characterize heart failure patients with ejection fraction levels below normal but greater than the definition of ‘reduced’ EF.
You may also be interested in...
Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.
Empire Building: Jardiance To Take ‘Special Place’ In Heart Failure
Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.
BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved
The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.